Clinical Trials Biogen’s Spinraza set to increase its chances to maintain a strong position in spinal muscular atrophy 12 Jan 2021
International update: Global Covid infections pass 95.6 million – WHO slams vaccine profiteers 19 Jan 2021
Boehringer Ingelheim ends BI 1467335 development for NASH Boehringer noted that other studies of BI 1467335 will continue unchanged. Credit: © Boehringer Ingelheim.
